# COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years — United States, June 1, 2023–September 30, 2025

**Authors:** Julia Raykin, Ilia Rochin, Ryan Wiegand, Victoria Soto, Afua Nyame-Mireku, Amy Chung, Josephine Mak, Tegan Boehmer, Pragna Patel

PMC · DOI: 10.15585/mmwr.mm7506a1 · Morbidity and Mortality Weekly Report · 2026-02-19

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382), death (MESH:D003643)
- **Chemicals:** remdesivir (MESH:C000606551), molnupiravir (MESH:C000656703), nirmatrelvir/ritonavir (MESH:C000719967)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12919849/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12919849/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12919849/full.md

---
Source: https://tomesphere.com/paper/PMC12919849